Alpharma’s Embeda Has “Incremental Benefit” In Reducing Opioid Abuse, FDA Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee expresses concern over variability in benefit seen among patients; many still experience euphoria sought by opioid abusers.
You may also be interested in...
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins
Pain Therapeutics’ Remoxy Is More Abuse-Resistant Than Other Oxycodone Formulations, FDA Panel Suggests
Approval may depend on FDA’s confidence that the firm’s proposed REMS can adequately monitor for abuse – a subject of apparent debate within FDA.